All listings for this product
Best-selling in Non-Fiction Books
Save on Non-Fiction Books
- AU $9.86Trending at AU $16.82
- AU $11.51Trending at AU $18.80
- AU $64.07Trending at AU $74.86
- AU $28.70Trending at AU $36.95
- AU $44.96Trending at AU $47.10
- AU $24.91Trending at AU $28.23
- AU $9.81Trending at AU $13.31
About this product
- DescriptionAs the generic pharmaceutical industry continues to grow and thrive, so does the need to conduct adequate, efficient bioequivalence studies. In recent years, there have been significant changes to the statistical models for evaluating bioequivalence. In addition, advances in the analytical techlogy used to detect drug and metabolite levels have made bioequivalence testing more complex. The second edition of Handbook of Bioequivalence Testing has been completely updated to include the most current information available, including new findings in drug delivery and dosage form design and revised worldwide regulatory requirements. New topics include: * A historical perspective on generic pharmaceuticals * New guidelines governing submissions related to bioequivalency studies, along with therapeutic code classifications * Models of ninferiority * Biosimilarity of large molecule drugs * Bioequivalence of complementary and alternate medicines * Bioequivalence of biosimilar therapeutic proteins and moclonal antibodies * New FDA guidelines for bioanalytical method validation * Outsourcing and monitoring of bioequivalence studies The cost of generic drugs is rising much faster than in the past, partly because of the increased costs required for approval-including those for bioequivalence testing. There is a dire need to re-examine the science behind this type of testing to reduce the burden of development costs-allowing companies to develop generic drugs faster and at a lower expense. The final chapter explores the future of bioequivalence testing and proposes radical changes in the process of biowaivers. It suggests how the cost of demonstrating bioequivalence can be reduced through intensive analytical investigation and proposes that regulatory agencies reduce the need for bioequivalence studies in humans. Backed by science and updated with the latest research, this book is destined to spark continued debate on the efficacy of the current bioequivalence testing paradigm.
- Author BiographySarfaraz K. Niazi, PhD, is the chairman and CEO of Therapeutic Proteins International, a world-class developer and manufacturer of biosimilar recombinant drugs. The company now leads the world in using innovative methods of manufacturing biosimilar recombinant drugs coming off-patents. He employs hundreds of world's top scientists working toward the goal of making life-saving biological drugs more affordable. He has published over 100 refereed research articles and abstracts, dozens of books, and hundreds of literary writings that span the vast areas of poetry, philosophy, rhetoric, irony, and modern dilemma.
- Author(s)Sarfaraz K. Niazi
- PublisherApple Academic Press Inc.
- Date of Publication25/11/2014
- SubjectIndustrial Chemistry & Manufacturing
- Series TitleDrugs and the Pharmaceutical Sciences
- Place of PublicationOakville
- Country of PublicationCanada
- ImprintApple Academic Press Inc.
- Content Note39 black & white illustrations, 116 black & white tables
- Weight1905 g
- Width178 mm
- Height254 mm
- Spine51 mm
- Format DetailsUnsewn / adhesive bound
- Edition Statement2nd Revised edition
This item doesn't belong on this page.
Thanks, we'll look into this.